Duffy S W, Day N E, Tabár L, Chen H H, Smith T C
MRC Biostatistics Unit, Institute of Public Health, Cambridge, United Kingdom.
J Natl Cancer Inst Monogr. 1997(22):93-7. doi: 10.1093/jncimono/1997.22.93.
Researchers have noted that mammographic screening has a reduced effect on breast cancer mortality in women in their forties compared to older women. Explanations for this include poorer sensitivity in younger women due to denser breast tissue, as well as more rapid tumor progression, giving a shorter mean sojourn time (the average duration of the preclinical screen-detectable period). To test these hypotheses, we developed a series of Markov-chain models to estimate tumor progression rates and sensitivity. Parameters were estimated using tumor data from the Swedish two-county trial of mammographic screening for breast cancer. The mean sojourn time was shorter in women aged 40-49 compared to women aged 50-59 and 60-69 (2.44, 3.70, and 4.17 years, respectively). Sensitivity was lower in the 40-49 age group compared to the two older groups (83%, 100%, and 100%, respectively). Thus, both rapid progression and poorer sensitivity are associated with the 40-49 age group. We also modeled tumor size, node status, and malignancy grade together with subsequent breast cancer mortality and found that, to achieve a reduction in mortality commensurate with that in women over 50, the interscreening interval for women in their forties should be less than two years. We conclude that Markov models and the use of tumor size, node status, and malignancy grade as surrogates for mortality can be useful in design and analysis of future studies of breast cancer screening.
研究人员指出,与老年女性相比,乳腺钼靶筛查对四十多岁女性乳腺癌死亡率的降低效果较差。对此的解释包括,年轻女性乳腺组织更致密,敏感性较差,以及肿瘤进展更快,导致平均停留时间较短(临床前可筛查期的平均持续时间)。为了验证这些假设,我们开发了一系列马尔可夫链模型来估计肿瘤进展率和敏感性。使用来自瑞典乳腺癌钼靶筛查两县试验的肿瘤数据估计参数。40 - 49岁女性的平均停留时间比50 - 59岁和60 - 69岁女性短(分别为2.44年、3.70年和4.17年)。40 - 49岁年龄组的敏感性低于两个年龄较大的组(分别为83%、100%和100%)。因此,快速进展和较差的敏感性都与40 - 49岁年龄组有关。我们还对肿瘤大小、淋巴结状态和恶性程度以及随后的乳腺癌死亡率进行了建模,发现为了实现与50岁以上女性相当的死亡率降低,四十多岁女性的筛查间隔应小于两年。我们得出结论,马尔可夫模型以及使用肿瘤大小、淋巴结状态和恶性程度作为死亡率的替代指标,可用于未来乳腺癌筛查研究的设计和分析。